Challenges and progress in the development of a serogroup B meningococcal vaccine

Expert Review of Vaccines

Volumn 8, Issue 6, 2009, Pages 729-745

  Lewis, Susan ^a   Sadarangani, Manish ^a   Hoe, J Claire ^a   Pollard, Andrew J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

5CVMB; Meningococcal disease; Outer membrane protein; Outer membrane vesicle vaccine; Serogroup B

Indexed keywords

MENINGOCOCCUS VACCINE;

EPIDEMIC; IMMUNE RESPONSE; IMMUNOGENICITY; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; REVIEW;

BIOMEDICAL RESEARCH; HUMANS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; SECRETORY VESICLES;

EID: 67049114125     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.30     Document Type: Review

References (153)

1. WHO. Control of Epidemic Meningococcal Disease: WHO Practical Guidelines, 2nd Edition. World Health Organization, Geneva, Switzerland (1998).
2. Trotter C, Samuelsson S, Perrocheau A et al. Ascertainment of meningococcal disease in Europe. Euro. Surveill. 10(12), 247-250 (2005).
3. Peltola H. Meningococcal disease: still with us. Rev. Infect. Dis. 5(1), 71-91 (1983).
4. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 20(Suppl. 1), S58-S67 (2001). (Pubitemid 32925012)
5. Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 326(7385), 365-366 (2003). (Pubitemid 36241472)
6. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364(9431), 365-367 (2004). (Pubitemid 38970013)
7. Mitka M. New vaccine should ease meningitis fears. JAMA 293(12), 1433-1434 (2005). (Pubitemid 40393280)
8. Healy CM, Baker CJ. The future of meningococcal vaccines. Pediatr. Infect. Dis. J. 24(2), 175-176 (2005). (Pubitemid 40250778)
9. Vaccination coverage among adolescents aged 13-17 years - United States, 2007. MMWR Morb. Mortal. Wkly Rep. 57(40), 1100-1103 (2008).
10. Snape MD, Perrett KP, Ford K et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants. JAMA 299, 173-184 (2008).
11. Wyle FA, Artenstein MS, Brandt BL et al. Immunologic response of man to group B meningococcal polysaccharide vaccines. J. Infect. Dis. 126(5), 514-521 (1972).
12. Devi SJ, Zollinger WD, Snoy PJ et al. Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys. Infect. Immun. 65(3), 1045-1052 (1997). (Pubitemid 27088008)
13. Zollinger WD, Moran EE, Devi SJ, Frasch CE. Bactericidal antibody responses of juvenile rhesus monkeys immunized with group B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines. Infect. Immun. 65(3), 1053-1060 (1997). (Pubitemid 27088009)
14. Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 2(8346), 355-357 (1983).
15. Howitz M, Krause TG, Simonsen JB et al. Lack of association between group B meningococcal disease and autoimmune disease. Clin. Infect. Dis. 45(10), 1327-1334 (2007).
16. Jennings HJ, Roy R, Gamian A. Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. J. Immunol. 137(5), 1708-1713 (1986). (Pubitemid 16014828)
17. Jennings HJ, Gamian A, Ashton FE. N-propionylated group B meningococcal polysaccharide mimics a unique epitope on group B Neisseria meningitidis. J. Exp. Med. 165(4), 1207-1211 (1987). (Pubitemid 17064516)
18. Ashton FE, Ryan JA, Michon F, Jennings HJ. Protective efficacy of mouse serum to the N-propionyl derivative of meningococcal group B polysaccharide. Microb. Pathog. 6(6), 455-458 (1989). (Pubitemid 19223600)
19. Moe GR, Flitter BA. Protective anti- N-propionyl Neisseria meningitidis group B polysaccharide monoclonal antibodies are reactive with non-capsular antigens expressed by group A, B, C and W135 strains. Presented at: International Pathogenic Neisseria Conference. Rotterdam, The Netherlands, 7-12 September 2008.
20. Bruge J, Bouveret-Le Cam N, Danve B, Rougon G, Schulz D. Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. Vaccine 22(9-10), 1087-1096 (2004). (Pubitemid 38296650)
21. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129(6), 1307-1326 (1969). • Describes how serum bactericidal antibody titers correlate with protection against meningococcal disease.
22. Borrow R, Andrews N, Goldblatt D, Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect. Immun. 69(3), 1568-1573 (2001). (Pubitemid 32187610)
23. Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection: serum bactericidal antibody activity. Vaccine 23(17-18), 2222-2227 (2005). (Pubitemid 40341456)
24. WHO. Requirements for meningococcal polysaccharide vaccine. In: World Health Organisation Technical Report Series. No. 594. World Health Organization, Geneva, Switzerland (1976).
25. Holst J, Feiring B, Fuglesang JE et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 21(7-8), 734-737 (2003). (Pubitemid 36091989)
26. Oster P, Lennon D, O'Hallahan J, Mulholland K, Reid S, Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 23(17-18), 2191-2196 (2005). • Summarizes clinical data in adults, children, toddlers and infants after immunization with the outer membrane vesicle (OMV) vaccine MeNZB™. (Pubitemid 40341449)
27. Trotter C, Findlow J, Balmer P et al. Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England. Clin. Vaccine Immunol. 14(7), 863-868 (2007).
28. Welsch JA, Granoff D. Immunity to Neisseria meningitidis group B in adults despite lack of serum bactericidal antibody. Clin. Vaccine Immunol. 14(12), 1596-1602 (2007).
29. Vermont CL, van Dijken HH, Kuipers AJ et al. Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine. Infect. Immun. 71(4), 1650-1655 (2003). (Pubitemid 36368693)
30. Martin DR, Ruijne N, McCallum L, O'Hallahan J, Oster P. The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin. Vaccine Immunol. 13(4), 486-491 (2006). (Pubitemid 44044834)
31. Findlow J, Holland A, Andrews N et al. Comparison of phenotypically indistinguishable but geographically distinct Neisseria meningitidis group B isolates in a serum bactericidal antibody assay. Clin. Vaccine Immunol. 14(11), 1451-1457 (2007). (Pubitemid 350304039)
32. Borrow R, Carlone GM, Rosenstein N et al. Neisseria meningitidis group B correlates of protection and assay standardization: international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine 24(24), 5093-5107 (2006). (Pubitemid 44209069)
33. Frasch CE, Van Alphen L, Holst J, Poolman JT, Rosenqvist E. Outer membrane protein vesicle vaccines for meningococcal disease. In: Meningococcal vaccines. Pollard AJ, Maiden MC (Eds). Humana Press Inc., NJ, USA 81-107 (2001). • Describes the process of OMV production, crucial to the development of many vaccines discussed in this review.
34. Tsai CM, Frasch CE, Rivera E, Hochstein HD. Measurements of lipopolysaccharide (endotoxin) in meningococcal protein and polysaccharide preparations for vaccine usage. J. Biol. Stand. 17(3), 249-258 (1989). (Pubitemid 19219369)
35. Hou VC, Koeberling O, Welsch JA, Granoff DM. Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870. J. Infect. Dis. 192(4), 580-590 (2005). (Pubitemid 41099306)
36. van der Voort ER, van der Ley P, van der Biezen J et al. Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine. Infect. Immun. 64(7), 2745-2751 (1996). (Pubitemid 26226842)
37. Wedege E, Hoiby EA, Rosenqvist E, Bjune G. Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian Serogroup B protection trial. Infect. Immun., 66(7), 3223-3231 (1998). (Pubitemid 28303120)
38. Idanpaan-Heikkila I, Hoiby EA, Chattopadhyay P, Airaksinen U, Michaelsen TM, Wedege E. Antibodies to meningococcal class 1 outer-membrane protein and its variable regions in patients with systemic meningococcal disease. J. Med. Microbiol. 43(5), 335-343 (1995).
39. van der Ley P, Heckels JE, Virji M, Hoogerhout P, Poolman JT. Topology of outer membrane porins in pathogenic Neisseria spp. Infect. Immun. 59(9), 2963-2971 (1991).
40. Holst J, Feiring B, Naess LM et al. The concept of 'tailor-made', protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine 23(17-18), 2202-2205 (2005).
41. Tappero JW, Lagos R, Ballesteros AM et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 281(16), 1520-1527 (1999). (Pubitemid 29200936)
42. Wedege E, Bolstad K, Aase A et al. Functional and specific antibody responses in adult volunteers in New Zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines. Clin. Vaccine Immunol. 14(7), 830-838 (2007).
43. Bjune G, Gronnesby JK, Hoiby EA, Closs O, Nokleby H. Results of an efficacy trial with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway. NIPH Ann. 14(2), 125-130 (1991).
44. Rodriguez AP, Dickinson F, Baly A, Martinez R. The epidemiological impact of antimeningococcal B vaccination in Cuba. Mem. Inst. Oswaldo Cruz 94(4), 433-440 (1999). (Pubitemid 129572516)
45. Sierra GV, Campa HC, Varcacel NM et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 14(2), 195-207 (1991).
46. Morley SL, Cole MJ, Ison CA et al. Immunogenicity of a serogroup B meningococcal vaccine against multiple Neisseria meningitidis strains in infants. Pediatr. Infect. Dis. J. 20(11), 1054-1061 (2001). (Pubitemid 33055077)
47. de Moraes JC, Perkins BA, Camargo MC et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 340(8827), 1074-1078 (1992).
48. Noronha CP, Struchiner CJ, Halloran ME. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study. Int. J. Epidemiol. 24(5), 1050-1057 (1995). (Pubitemid 26466129)
49. Perkins BA, Jonsdottir K, Briem H et al. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J. Infect. Dis. 177(3), 683-691 (1998). (Pubitemid 28099883)
50. Rosenqvist E, Hoiby EA, Wedege E et al. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect. Immun. 63(12), 4642-4652 (1995).
51. Holst J, Aaberge I, Oster P et al. A 'tailor made' vaccine trialled as part of public health response to group B meningococcal epidemic in New Zealand. Eurosurveillance 7(30) (2003)
52. Rosenqvist E, Bryn K, Harbak K et al. Development of a tailor-made outer membrane vesicle vaccine against the group B meningococcal epidemic in New Zealand. Presented at: International Pathogenic Neisseria Conference. Oslo, Norway, 1-6 September 2002.
53. Wong S, Lennon D, Jackson C et al. New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months. Pediatr. Infect. Dis. J. 26(4), 345-350 (2007). (Pubitemid 46596661)
54. Thornton V, Lennon D, Rasanathan K et al. Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control. Vaccine 24(9), 1395-1400 (2006). (Pubitemid 43222049)
55. Oster P, O'Hallahan J, Aaberge I, Tilman S, Ypma E, Martin D. Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand. Vaccine 25(16), 3075-3079 (2007). (Pubitemid 46482737)
56. Kelly C, Arnold R, Galloway Y, O'Hallahan J. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am. J. Epidemiol. 166(7), 817-823 (2007). (Pubitemid 47428901)
57. Galloway Y, Stehr-Green P, McNicholas A, O'Hallahan J. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int. J. Epidemiol. (2008).
58. Martin D, Lopez L. Has MeNZBTM controlled New Zealand's epidemic? Presented at: International Pathogenic Neisseria Conference. Rotterdam, The Netherlands, 7-12 September 2008.
59. Martin D, Lopez L. The Epidemiology of Meningococcal Disease in New Zealand in 2007. Institute of Environmental Science and Research (2008).
60. Sotolongo Padron F, Campa Huergo C, Casanueva Gil V, Fajardo Diaz E, Cuevas Valdespino IE, Gonzalez Gotera N. Cuban meningococcal BC vaccine: experiences & contributions from 20 years of application. MEDICC Rev. 9(1), 16-22 (2007).
61. Nokleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, Oster P. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease. Vaccine 25(16), 3080-3084 (2007). (Pubitemid 46505045)
62. WHO. Safety of meningococcal B vaccines. Wkly Epidemiol. Rec. (83), 37-44 (2008).
63. Noblet C, Cordier L, Massy N, Jacquet A, Thuillez C. Meningococcal serogroup B vaccine (MenBvac): pharmacovigilance follow-up of the vaccination campaign in the department of Seine-Maritime (Upper-Normandy). Fundam. Clin. Pharmacol. 21(s1), 7 (2007).
64. Taha MK, Zarantonelli ML, Alonso JM et al. Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks. Vaccine 25(14), 2537-2538 (2007). (Pubitemid 46400920)
65. Gold R, Goldschneider I, Lepow ML, Draper TF, Randolph M. Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children. J. Infect. Dis. 137(2), 112-121 (1978). (Pubitemid 8289151)
66. Cartwright KA, Stuart JM, Jones DM, Noah ND. The Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica. Epidemiol. Infect. 99(3), 591-601 (1987). (Pubitemid 18034332)
67. Oliver KJ, Reddin KM, Bracegirdle P et al. Neisseria lactamica protects against experimental meningococcal infection. Infect. Immun. 70(7), 3621-3626 (2002). (Pubitemid 34666000)
68. Li Y, Zhang Q, Winterbotham M, Mowe E, Gorringe A, Tang CM. Immunization with live Neisseria lactamica protects mice against meningococcal challenge and can elicit serum bactericidal antibodies. Infect. Immun. 74(11), 6348-6355 (2006). (Pubitemid 44657417)
69. Gorringe AR, Matheson M, Taylor S et al. Safety and immunogenicity of a meningococcal disease vaccine base on Neisseria lactamica in adult volunteers. Presented at: International Pathogenic Neisseria Conference. Rotterdam, The Netherlands, 7-12 September 2008.
70. Haneberg B, Dalseg R, Wedege E et al. Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans. Infect. Immun. 66(4), 1334-1341 (1998). (Pubitemid 128471487)
71. Findlow J, Taylor S, Aase A et al. Comparison and correlation of Neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac. Infect. Immun. 74(8), 4557-4565 (2006). (Pubitemid 44157242)
72. Ala'Aldeen DA, Stevenson P, Griffiths E et al. Immune responses in humans and animals to meningococcal transferrin-binding proteins: implications for vaccine design. Infect. Immun. 62(7), 2984-2990 (1994). (Pubitemid 24203987)
73. Johnson AS, Gorringe AR, Fox AJ, Borrow R, Robinson A. Analysis of the human Ig isotype response to individual transferrin binding proteins A and B from Neisseria meningitidis. FEMS Immunol. Med. Microbiol. 19(2), 159-167 (1997). (Pubitemid 27467069)
74. Irwin SW, Averil N, Cheng CY, Schryvers AB. Preparation and analysis of isogenic mutants in the transferrin receptor protein genes, tbpA and tbpB, from Neisseria meningitidis. Mol. Microbiol. 8(6), 1125-1133 (1993). (Pubitemid 23187031)
75. Cornelissen CN, Biswas GD, Sparling PF. Expression of gonococcal transferrin-binding protein 1 causes Escherichia coli to bind human transferrin. J. Bacteriol. 175(8), 2448-2450 (1993). (Pubitemid 23123522)
76. Gray-Owen SD, Schryvers AB. Bacterial transferrin and lactoferrin receptors. Trends Microbiol. 4(5), 185-191 (1996). (Pubitemid 26162132)
77. Danve B, Lissolo L, Mignon M et al. Transferrin-binding proteins isolated from Neisseria meningitidis elicit protective and bactericidal antibodies in laboratory animals. Vaccine 11(12), 1214-1220 (1993). (Pubitemid 23308778)
78. Lissolo L, Maitre-Wilmotte G, Dumas P, Mignon M, Danve B, Quentin-Millet MJ. Evaluation of transferrin-binding protein 2 within the transferrin-binding protein complex as a potential antigen for future meningococcal vaccines. Infect. Immun. 63(3), 884-890 (1995).
79. Rokbi B, Mazarin V, Maitre-Wilmotte G, Quentin-Millet MJ. Identification of two major families of transferrin receptors among Neisseria meningitidis strains based on antigenic and genomic features. FEMS Microbiol. Lett. 110(1), 51-57 (1993). (Pubitemid 23171227)
80. Rokbi B, Mignon M, Caugant DA, Quentin-Millet MJ. Heterogeneity of tbpB, the transferrin-binding protein B gene, among serogroup B Neisseria meningitidis strains of the ET-5 complex. Clin. Diagn. Lab. Immunol. 4(5), 522-529 (1997). (Pubitemid 27448616)
81. Danve B, Lissolo L, Guinet F et al. Safety and immunogenicity of a Neisseria meningitidis group B transferrin binding protein vaccine in adults. Presented at: 11th International Pathogenic Neisseria Conference. Nice, France, 1-6 November 1998.
82. Virji M, Makepeace K, Ferguson DJ, Achtman M, Moxon ER. Meningococcal Opa and Opc proteins: their role in colonization and invasion of human epithelial and endothelial cells. Mol. Microbiol. 10(3), 499-510 (1993). (Pubitemid 23334431)
83. Callaghan MJ, Jolley KA, Maiden MC. Opacity-associated adhesin repertoire in hyperinvasive Neisseria meningitidis. Infect. Immun. 74(9), 5085-5094 (2006). (Pubitemid 44300426)
84. Callaghan MJ, Lewis S, Bailey SE et al. Evaluation of recombinant Opa proteins as vaccine candidates against hyperinvasive meningococci. Presented at: International Pathogenic Neisseria Conference. Rotterdam, The Netherlands, 7-12 September 2008.
85. Wiertz EJ, Delvig A, Donders EM et al. T-cell responses to outer membrane proteins of Neisseria meningitidis: comparative study of the Opa, Opc, and PorA proteins. Infect. Immun. 64(1), 298-304 (1996). (Pubitemid 26009369)
86. + T lymphocytes. Nat. Immunol. 3(3), 229-236 (2002).
87. Lee HS, Boulton IC, Reddin K et al. Neisserial outer membrane vesicles bind the coinhibitory receptor carcinoembryonic antigen-related cellular adhesion molecule 1 and suppress CD4+ T lymphocyte function. Infect. Immun. 75(9), 4449-4455 (2007). (Pubitemid 47378103)
88. Martin D, Cadieux N, Hamel J, Brodeur BR. Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J. Exp. Med. 185(7), 1173-1183 (1997). (Pubitemid 27172898)
89. Cadieux N, Plante M, Rioux CR, Hamel J, Brodeur BR, Martin D. Bactericidal and cross-protective activities of a monoclonal antibody directed against Neisseria meningitidis NspA outer membrane protein. Infect. Immun. 67(9), 4955-4959 (1999). (Pubitemid 29400491)
90. Martin D, Brodeur BR, Hamel J et al. Candidate Neisseria meningitidis NspA vaccine. J. Biotechnol. 83(1-2), 27-31 (2000).
91. Halperin SA, Langley JM, Smith B et al. Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults. Vaccine 25(3), 450-457 (2007). (Pubitemid 44856095)
92. Moe GR, Tan S, Granoff DM. Differences in surface expression of NspA among Neisseria meningitidis group B strains. Infect. Immun. 67(11), 5664-5675 (1999). (Pubitemid 29508084)
93. Scholten RJ, Kuipers B, Valkenburg HA, Dankert J, Zollinger WD, Poolman JT. Lipo-oligosaccharide immunotyping of Neisseria meningitidis by a whole-cell ELISA with monoclonal antibodies. J. Med. Microbiol. 41(4), 236-243 (1994). (Pubitemid 24333789)
94. Jakel A, Plested JS, Hoe JC et al. Naturally-occurring human serum antibodies to inner core lipopolysaccharide epitopes of Neisseria meningitidis protect against invasive meningococcal disease caused by isolates displaying homologous inner core structures. Vaccine 26(51), 6655-6663 (2008).
95. Griffiss JM, Brandt BL, Broud DD, Goroff DK, Baker CJ. Immune response of infants and children to disseminated infections with Neisseria meningitidis. J. Infect. Dis. 150(1), 71-79 (1984). (Pubitemid 14093836)
96. Plested JS, Gidney MA, Coull PA et al. Enzyme linked immunosorbent assay (ELISA) for the detection of serum antibodies to the inner core lipopolysaccharide of Neisseria meningitidis group B. J. Immunol. Methods 237(1-2), 73-84 (2000). (Pubitemid 30139504)
97. Drabick JJ, Brandt BL, Moran EE, Saunders NB, Shoemaker DR, Zollinger WD. Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers. Vaccine 18(1-2), 160-172 (1999). (Pubitemid 29432149)
98. Poolman JT. Polysaccharides and membrane vaccines. In: Bacterial Vaccines. Mizrahi A (Ed.). John Wiley and Sons Ltd, New York, USA, 57-86 (1990).
99. Tsai CM, Civin CI. Eight lipooligosaccharides of Neisseria meningitidis react with a monoclonal antibody which binds lacto-N-neotetraose (Gal β 1-4GlcNAc β 1-3Gal β 1-4Glc). Infect. Immun. 59(10), 3604-3609 (1991).
100. Jennings MP, Srikhanta YN, Moxon ER et al. The genetic basis of the phase variation repertoire of lipopolysaccharide immunotypes in Neisseria meningitidis. Microbiology 145(Pt 11), 3013-3021 (1999). (Pubitemid 29535022)
101. van der Ley P, Steeghs L. Lessons from an LPS-deficient Neisseria meningitidis mutant. J. Endotoxin Res. 9(2), 124-128 (2003). (Pubitemid 36603688)
102. Zollinger WD, Moran EE, Ray J, McClain B. Phase I safety and immunogenicity study of a meningococcal outer membrane protein, detoxified LPS vaccine. Presented at: Frontiers in Vaccine Research. Hanasaari, Finland, 9-11 September 1991.
103. Plested JS, Ferry BL, Coull PA et al. Functional opsonic activity of human serum antibodies to inner core lipopolysaccharide (GalE) of serogroup B meningococci measured by flow cytometry. Infect. Immun. 69(5), 3203-3213 (2001). (Pubitemid 32332218)
104. Plested JS, Makepeace K, Jennings MP et al. Conservation and accessibility of an inner core lipopolysaccharide epitope of Neisseria meningitidis. Infect. Immun. 67(10), 5417-5426 (1999). (Pubitemid 29455320)
105. Plested JS, Harris SL, Wright JC et al. Highly conserved Neisseria meningitidis inner-core lipopolysaccharide epitope confers protection against experimental meningococcal bacteremia. J. Infect. Dis. 187(8), 1223-1234 (2003). (Pubitemid 36438962)
106. Pavliak V, Fortuna-Nevin M, Monteiro M, Mason K, Zhu D. Neisseria meningitidis LOS conjugate vaccine against meningococcal disease. Presented at: 14th International Pathogenic Neisseria Conference. Milwaukee, WI, USA, 5-10 September 2004.
107. Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 19(17-19), 2688-2691 (2001). (Pubitemid 32234290)
108. Pizza M, Scarlato V, Masignani V et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287(5459), 1816-1820 (2000).
109. Comanducci M, Bambini S, Brunelli B et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J. Exp. Med. 195(11), 1445-1454 (2002). (Pubitemid 34602821)
110. Norheim G, Aseffa A, Yassin MA et al. Specificity of the sub-capsular antibody responses following serogroup A meningococcal disease in Ethiopian patients. Clin. Vaccine Immunol. 15(5), 863-871 (2008).
111. Bowe F, Lavelle EC, McNeela EA et al. Mucosal vaccination against serogroup B meningococci: induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin. Infect. Immun. 72(7), 4052-4060 (2004). (Pubitemid 38821920)
112. Ciabattini A, Giomarelli B, Parigi R et al. Intranasal immunization of mice with recombinant Streptococcus gordonii expressing NadA of Neisseria meningitidis induces systemic bactericidal antibodies and local IgA. Vaccine 26(33), 4244-4250 (2008).
113. Beernink PT, Welsch JA, Harrison LH, Leipus A, Kaplan SL, Granoff DM. Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine. J. Infect. Dis. 195(10), 1472-1479 (2007). (Pubitemid 46717465)
114. Lucidarme J, Comanducci M, Findlow J et al. The presence and genetic diversity of three meningococcal vaccine candidate genes, nadA, fHbp and gna2132, in ST-269 clonal complex isolates in England and Wales. Presented at: International Pathogenic Neisseria Conference. Rotterdam, The Netherlands, 7-12 September 2008.
115. Lex A, Wiesmuller KH, Jung G, Bessler WG. A synthetic analogue of Escherichia coli lipoprotein, tripalmitoyl pentapeptide, constitutes a potent immune adjuvant. J. Immunol. 137(8), 2676-2681 (1986). (Pubitemid 17176628)
116. Fletcher LD, Bernfield L, Barniak V et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect. Immun. 72(4), 2088-2100 (2004). (Pubitemid 38419922)
117. Masignani V, Comanducci M, Giuliani MM et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J. Exp. Med. 197(6), 789-799 (2003). (Pubitemid 36350873)
118. Zhu D, Barniak V, Zhang Y, Green B, Zlotnick G. Intranasal immunization of mice with recombinant lipidated P2086 protein reduces nasal colonization of group B Neisseria meningitidis. Vaccine 24(26), 5420-5425 (2006). (Pubitemid 43831373)
119. Zhu D, Zhang Y, Barniak V, Bernfield L, Howell A, Zlotnick G. Evaluation of recombinant lipidated P2086 protein as a vaccine candidate for group B Neisseria meningitidis in a murine nasal challenge model. Infect. Immun. 73(10), 6838-6845 (2005). (Pubitemid 41368851)
120. Pillai S, Howell A, Alexander K et al. Outer membrane protein (OMP) based vaccine for Neisseria meningitidis serogroup B. Vaccine 23(17-18), 2206-2209 (2005). (Pubitemid 40341452)
121. Murphy E, Andrew L, Lee KL et al. Sequence diversity of vaccine candidate LP2086 in Neisseria meningitidis serogroup B strains causing invasive disease. Presented at: International Pathogenic Neisseria Conference. Rotterdam, The Netherlands, 7-12 September 2008.
122. Jiang HQ, Harris SL, Tan C et al. Prediction of broad vaccine coverage for a bivalent rLP2086 based vaccine which elicits serum bactericidal activity against a diverse collection of serogroup B Meningococci. Presented at: International Pathogenic Neisseria Conference. Rotterdam, The Netherlands, 7-12 September 2008.
123. Anderson AS, Xu R, Tan C et al. Functional cross-reactive antibodies are elicited by a Group B Neisseria meningitidis bivalent recombinant lipidated LP2086 vaccine in Cynomolgus macaques. Presented at: International Pathogenic Neisseria Conference. Rotterdam, The Netherlands, 7-12 September 2008.
124. Nissen MD, Marshall HS, Richmond P et al. A randomised, placebo-controlled, double-blind, Phase I trial of ascending doses of meningococcal group B rLP2086 vaccine. Presented at: 26th Annual Meeting of the European Society for Paediatric Infectious Diseases. Graz, Austria, 13-17 May 2008.
125. Richmond P, Marshall HS, Nissen MD et al. A randomized, observed-blinded, active control, Phase 1 trial of meningococcal serogroup B rLP2086 vaccine in healthy children and adolescent aged 8 to 14 years. Presented at: International Pathogenic Neisseria Conference. Rotterdam, The Netherlands, 7-12 September 2008.
126. Welsch JA, Rossi R, Comanducci M, Granoff DM. Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. J. Immunol. 172(9), 5606-5615 (2004).
127. Welsch JA, Ram S, Koeberling O, Granoff DM. Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J. Infect. Dis. 197(7), 1053-1061 (2008).
128. Seib KL, Serruto D, Oriente F et al. Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37. Infect. Immun. 77(1), 292-299 (2009).
129. Giuliani MM, Adu-Bobie J, Comanducci M et al. A universal vaccine for serogroup B meningococcus. Proc. Natl Acad. Sci. USA 103(29), 10834-10839 (2006). •• Describes the production and preclinical testing of the first serogroup B vaccine based on antigens identified by reverse vaccinology. (Pubitemid 44148381)
130. Snape MD, Dawson T, Morant A et al. immungenicity and reactogenicity of a novel serogroup B Neisseria meningitidis vaccine administered from 6 months of age. Presented at: International Pathogenic Neisseria Conference. Rotterdam, The Netherlands, 7-12 September 2008.
131. Miller E, Pollard AJ, Borrow R et al. Safety and immunogenicity of Novartis meningoccocal serogroup B vaccine (MenB vaccine) after three doses adminstered in infancy. Presented at: 26th Annual Meeting of the European Society for Paediatric Infectious Diseases. Graz, Austria, 13-17 May 2008.
132. Welsch JA, Moe GR, Rossi R, Adu-Bobie J, Rappuoli R, Granoff DM. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J. Infect. Dis. 188(11), 1730-1740 (2003). (Pubitemid 38010685)
133. de Kleijn ED, de Groot R, Lafeber AB et al. Immunogenicity and safety of monovalent p1.7(h),4 meningococcal outer membrane vesicle vaccine in toddlers: comparison of two vaccination schedules and two vaccine formulations. Vaccine 19(9-10), 1141-1148 (2000). (Pubitemid 32008280)
134. Claassen I, Meylis J, van der Ley P et al. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 14(10), 1001-1008 (1996). (Pubitemid 26271074)
135. van den Dobbelsteen GP, van Dijken HH, Pillai S, van Alphen L. Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs. Vaccine 25(13), 2491-2496 (2007). (Pubitemid 46366130)
136. Abdillahi H, Poolman JT. Neisseria meningitidis group B serosubtyping using monoclonal antibodies in whole-cell ELISA. Microb. Pathog. 4(1), 27-32 (1988). (Pubitemid 18103739)
137. Tondella ML, Popovic T, Rosenstein NE et al. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team. J. Clin. Microbiol. 38(9), 3323-3328 (2000).
138. van der Ley P, van der Biezen J, Poolman JT. Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine. Vaccine 13(4), 401-407 (1995).
139. Cartwright K, Morris R, Rumke H et al. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine 17(20-21), 2612-2619 (1999). (Pubitemid 29314456)
140. Luijkx TA, van Dijken H, Hamstra HJ et al. Relative immunogenicity of PorA subtypes in a multivalent Neisseria meningitidis vaccine is not dependent on presentation form. Infect. Immun. 71(11), 6367-6371 (2003). (Pubitemid 37337695)
141. de Kleijn ED, de Groot R, Labadie J et al. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age. Vaccine 18(15), 1456-1466 (2000). (Pubitemid 30017826)
142. Luijkx T, van Dijken H, van Els C, van den Dobbelsteen G. Heterologous prime-boost strategy to overcome weak immunogenicity of two serosubtypes in hexavalent Neisseria meningitidis outer membrane vesicle vaccine. Vaccine 24(10), 1569-1577 (2006). (Pubitemid 43238232)
143. Boutriau D, Poolman J, Borrow R et al. Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents. Clin. Vaccine Immunol. 14(1), 65-73 (2007).
144. Sandbu S, Feiring B, Oster P et al. Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines. Clin. Vaccine Immunol. 14(9), 1062-1069 (2007). (Pubitemid 47518071)
145. Weynants VE, Feron CM, Goraj KK et al. Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis. Infect. Immun. 75(11), 5434-5442 (2007). (Pubitemid 350033632)
146. Saunders NB, Shoemaker DR, Brandt BL, Moran EE, Larsen T, Zollinger WD. Immunogenicity of intranasally administered meningococcal native outer membrane vesicles in mice. Infect. Immun. 67(1), 113-119 (1999). (Pubitemid 29021637)
147. Katial RK, Brandt BL, Moran EE, Marks S, Agnello V, Zollinger WD. Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine. Infect. Immun. 70(2), 702-707 (2002). (Pubitemid 34083831)
148. Fisseha M, Chen P, Brandt B, Kijek T, Moran E, Zollinger W. Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination. Infect. Immun. 73(7), 4070-4080 (2005). (Pubitemid 40923147)
149. Keiser PB, Moran EE, Schmeil DH et al. A Phase 1 study of the safety and immunogenicity of an intramuscular group B meningococcal NOMV vaccine made from an lpxL2 and synX deleted strain. Presented at: International Pathogenic Neisseria Conference. Rotterdam, The Netherlands, 7-12 September 2008.
150. Donets M, Fisseha M, Kijek T et al. Genetic modifications of three meningococcal group B multivalent vaccine strains. Presented at: International Pathogenic Neisseria Conference. Rotterdam, The Netherlands, 7-12 September 2008.
151. Labrie JE, Donets M, Ionin B et al. Immunogenicity of a native outer membrane vesicle vaccine for Neisseria meningitidis serogroup B in rabbits. Presented at: International Pathogenic Neisseria Conference. Rotterdam, The Netherlands, 7-12 September 2008.
152. Pinto VB, Moran E, Schmiel D et al. Analysis of the immune response to an investigational three componenet N. menigitidis NOMV vaccine in mice. Presented at: International Pathogenic Neisseria Conference. Rotterdam, The Netherlands, 7-12 September 2008.
153. EU-IBIS. Invasive Neisseria meningitidis in Europe 2006. Health Protection Agency, London, UK 2006.